Scienza e Tecnologia
Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and Development of Newer Therapies During the Study Period (2020-2034) | DelveInsight
Discover more about the treatment resistant hypertension treatment market @
The treatment resistant hypertension market dynamics are expected to change in the coming years. , along with innovations in pharmacogenomics, precision medicine, and digital health platforms, are expanding the landscape of treatment options for TRH by enabling , and necessitating multidisciplinary collaboration among cardiologists, nephrologists, endocrinologists, and other specialists for comprehensive care.
Furthermore, potential therapies are being investigated for treatment resistant hypertension, and it is safe to predict that the treatment space will significantly impact the treatment resistant hypertension market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the treatment resistant hypertension market in the 7MM.
However, several factors may impede the growth of the treatment resistant hypertension market. Managing TRH often necessitates complex medication regimens and lifestyle modifications, leading to ; however, despite therapeutic advancements, a subset of patients , underscoring the need for alternative strategies, even as delay new therapy development and adoption, further compounded by the TRH places on healthcare systems, highlighting the urgent need for cost-effective solutions.
Furthermore, the treatment resistant hypertension market growth may be offset by , , , and a . In addition, the about the disease may also impact the treatment resistant hypertension market growth.
Resistant hypertension is managed through a combination of lifestyle modifications, pharmacological therapy, and, when necessary, interventional procedures. Key lifestyle changes include maintaining a healthy weight through regular exercise and a balanced diet, reducing salt intake, limiting alcohol consumption, and quitting smoking. Pharmacological treatment typically involves a combination of a renin–angiotensin system inhibitor, a long-acting calcium channel blocker, and a diuretic at the highest tolerable doses, preferably as a single-pill formulation. Spironolactone is currently the preferred fourth-line agent, while alternatives include alpha-blockers, beta-blockers, centrally acting sympatholytics, and vasodilators. For patients whose blood pressure remains uncontrolled despite these strategies, options such as renal denervation and emerging drug therapies should be considered.
Lifestyle interventions are particularly important, with a recent meta-analysis identifying them as the most effective non-pharmacologic approach, achieving a reduction in office systolic blood pressure by approximately 7.26 mmHg. Dietary patterns such as the DASH and Mediterranean diets, characterized by high intake of fruits, vegetables, whole grains, and low-fat dairy, and low levels of saturated fats and sugars, have shown proven benefit. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, offers a promising alternative by blocking aldosterone activity even in its absence. While spironolactone remains the standard add-on therapy, its anti-androgenic effects may limit its use, especially in men or those with hyperkalemia.
marks a significant advancement as the first antihypertensive from a new drug class in over three decades, targeting the endothelin pathway. Approved by the FDA in early 2024, TRYVIO is a convenient once-daily oral therapy that simplifies prescribing and adherence. The removal of the REMS requirement by the FDA signals increased confidence in its safety. Though it's now available for patients at high cardiovascular risk, fluid retention, reported in 18% of patients at higher doses, which may affect its adoption compared to existing options. While Idorsia has not yet revealed a global commercialization partner, the positive Phase III outcomes indicate strong market potential for TRYVIO.
To know more about FDA-approved drugs for treatment resistant hypertension, visit @
Several TRH drugs with different mechanisms of action that are in development are (baxdrostat, lorundrostat), (MANP), (REGN5381), (zilebesiran), and (tonlamarsen). The success of these candidates could diversify the treatment landscape and intensify competition.
is an oral, small-molecule drug that selectively inhibits aldosterone synthase, the enzyme responsible for producing aldosterone in the adrenal glands. Baxdrostat emerges as a in the resistant hypertension pipeline, with AstraZeneca positioning it as a potential . As an oral , it targets patients with uncontrolled or resistant hypertension. The Phase II results have shown in SBP, outperforming TRYVIO, with a favorable safety profile. First, mention the drug's current phase. The , expected in the , will be key in validating its commercial and clinical potential.
, another Phase III investigational oral therapy. It is gaining attention as a in the antihypertensive market. Developed by , the drug is a , and early data positions it as a potential best-in-class option for patients with resistant or uncontrolled hypertension. from both the Phase II Advance-HTN and Phase III Launch-HTN trials validate its clinical promise, with in terms of blood pressure reduction. What further strengthens Lorundrostat's profile is its . With approximately , the drug may offer a more targeted approach to managing cardiorenal metabolic conditions, a segment with significant unmet clinical needs.
The anticipated launch of these emerging therapies are poised to transform the treatment resistant hypertension market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the treatment resistant hypertension market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about treatment resistant hypertension drugs in development @
Resistant hypertension is characterized by blood pressure that remains elevated at or above 130 mmHg systolic and 80 mmHg diastolic, despite the use of three or four different classes of antihypertensive medications, including a thiazide diuretic, all at their highest tolerated doses. It can also refer to cases where blood pressure is controlled, but only with the use of four or more antihypertensive agents. This definition encompasses both resistant and refractory hypertension in patients whose blood pressure remains uncontrolled despite being on an adequate regimen that includes a diuretic. Individuals who require more than three medications to control their blood pressure may also benefit from referral to a hypertension specialist.
The assessment of resistant hypertension begins with confirming the accuracy of blood pressure readings, as mistakes such as using an improperly sized cuff or incorrect arm positioning can lead to misleadingly high values. It is also important to rule out the white coat effect by using validated out-of-office monitoring methods, such as ambulatory or home blood pressure monitoring under clinical guidelines. Automated office blood pressure (AOBP) measurement, which involves repeated readings taken every 1–2 minutes with the patient alone in a quiet room using a specialized oscillometric device, is a useful technique to reduce this effect.
The treatment resistant hypertension epidemiology section provides insights into the historical and current treatment resistant hypertension patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The treatment resistant hypertension market report offers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Download the report to understand the treatment resistant hypertension market trends @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the TRH epidemiology trends.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypertension companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertension companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TKIs companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/treatment-resistant-hypertension-market-set-to-transform-at-a-cagr-of-5-with-increasing-diagnosis-and-treatment-of-resistant-patients-along-with-approval-and-development-of-newer-therapies-during-the-study-period-20202034--de-302518618.html